PT Kalbe Farma Tbk
Research PT Kalbe Farma Tbk (LCLA) on Bullrun: market cap EUR 1.40B, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLCLA
- ExchangeF
- CountryIndonesia
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Market capEUR 1.40B
- Dividend yield3.1%
- Financial periodQ1 2026
- RevenueIDR 9.68T
- Net incomeIDR 1.03T
- Free cash flowIDR 89.42B
- Gross margin37.9%
Valuation Snapshot
latest market cap is EUR 1.40B; dividend yield is 3.1%.
Peer valuation comparison
Latest dividend yield is 3.11% versus a Healthcare sector median of 2.11% (47.4% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 1.40B | n/a | 3.2% | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR, yield 3.1%.
About PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PT Kalbe Farma Tbk's market cap?
PT Kalbe Farma Tbk's market capitalization is EUR 1.40B.
Does PT Kalbe Farma Tbk pay a dividend?
PT Kalbe Farma Tbk has a dividend yield of 3.1%.
What does PT Kalbe Farma Tbk do?
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products.